Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 615,615
  • Shares Outstanding, K 32,147
  • Annual Sales, $ 9,330 K
  • Annual Income, $ -78,280 K
  • 60-Month Beta 1.58
  • Price/Sales 65.64
  • Price/Cash Flow N/A
  • Price/Book 6.38
Trade SPRO with:

Options Overview

Details
  • Implied Volatility 91.88%
  • Historical Volatility 62.92%
  • IV Percentile 46%
  • IV Rank 29.93%
  • IV High 128.74% on 09/24/20
  • IV Low 76.14% on 05/26/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 406
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 362
  • Open Int (30-Day) 952

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.74
  • Number of Estimates 3
  • High Estimate -0.69
  • Low Estimate -0.82
  • Prior Year -0.86
  • Growth Rate Est. (year over year) +13.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.10 +21.01%
on 08/23/21
19.82 -7.82%
on 09/17/21
+2.81 (+18.18%)
since 08/20/21
3-Month
12.75 +43.29%
on 08/17/21
19.82 -7.82%
on 09/17/21
+3.60 (+24.54%)
since 06/18/21
52-Week
9.25 +97.51%
on 09/28/20
23.64 -22.71%
on 12/28/20
+8.16 (+80.71%)
since 09/18/20

Most Recent Stories

More News
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

NVS : 83.11 (-0.44%)
BGNE : 402.53 (-0.15%)
CRVS : 4.98 (-6.39%)
SPRO : 18.22 (-4.86%)
Spero Therapeutics to Present Data at IDWeek 2021

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.22 (-4.86%)
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal....

RDHL : 4.77 (-2.45%)
VTVT : 1.7400 (-2.25%)
CRVS : 4.98 (-6.39%)
SPRO : 18.22 (-4.86%)
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

ALNY : 185.28 (-2.66%)
VRTX : 187.27 (-0.55%)
CRVS : 4.98 (-6.39%)
SPRO : 18.22 (-4.86%)
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA

The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.

NVS : 83.11 (-0.44%)
BGNE : 402.53 (-0.15%)
CRVS : 4.98 (-6.39%)
SPRO : 18.22 (-4.86%)
Apellis (APLS) Down on Mixed Data From Studies on GA Candidate

Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.

AZN : 58.25 (+4.84%)
CRVS : 4.98 (-6.39%)
SPRO : 18.22 (-4.86%)
APLS : 33.80 (-1.20%)
Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study

Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.

PFE : 44.36 (+1.07%)
LLY : 232.36 (+0.98%)
SPRO : 18.22 (-4.86%)
ERAS : 19.57 (+0.77%)
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review

The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.

VRTX : 187.27 (-0.55%)
GBT : 27.05 (-3.50%)
CRVS : 4.98 (-6.39%)
SPRO : 18.22 (-4.86%)
Spero Therapeutics to Present at Three Upcoming Investor Conferences

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.22 (-4.86%)
Precision (DTIL) Inks Deal With Tiziana for Cancer Candidate

Precision (DTIL) signs an exclusive license agreement with Tiziana to explore the latter's fully human anti-CD3 mAb, foralumab, for treating various cancer indications. Stock up.

CRVS : 4.98 (-6.39%)
SPRO : 18.22 (-4.86%)
TLSA : 1.5800 (-7.06%)
DTIL : 12.62 (-1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 20.60
2nd Resistance Point 20.21
1st Resistance Point 19.68
Last Price 18.22
1st Support Level 18.76
2nd Support Level 18.37
3rd Support Level 17.84

See More

52-Week High 23.64
Last Price 18.22
Fibonacci 61.8% 18.14
Fibonacci 50% 16.44
Fibonacci 38.2% 14.75
52-Week Low 9.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar